TNFα inhibitor treatment trajectories learnings on biosimilars from clinical practice
- Promovendus Dr. Rosanne Meijboom
- Promoters Prof. dr A.C.G. Egberts
- Co-Promoters Dr. T.J. Giezen Dr. H. Gardarsdottir
- Jaar 2023
In this thesis, insight into the TNFα inhibitor treatment trajectories of patients with immune-mediated inflammatory diseases (IMIDs) IMIDs was provided. About one in six IMID patients TNFα inhibitor treatment switched biological treatment, mainly to another TNFα inhibitor. Determinants for switching, e.g. TNFα inhibitor serum drug measurement, TNFα inhibitor dose escalation and initiating corticosteroids, indicated disease worsening.